Those Who Give the COVID-19 Vaccine Need to Be Trained to Use an EpiPen

Now that vaccines protecting people from the corona virus have arrived, the danger of dangerous attacks of anaphylaxis have arrived as well. Proper administration of epinephrine is now almost as important as using the vaccine itself. Our association fully supports comprehensive training on how to use an epinephrine auto-injector (EAI) device in an anaphylaxis emergency.

Those Who Give the COVID-19 Vaccine Need to Be Trained to Use an EpiPen

Nurse Receiving Covid-19 Vaccine Dec 2020
(AP Photo/Mark Lennihan, Pool) AP

By Robert K. Houton

The COVID-19 vaccination that began rolling out this week to frontline medical workers will hopefully end our long nightmare with this virus and the pandemic. But there is one concern: 1.6% of the American population, or roughly 5 million people, have experienced a severe allergic attack, called anaphylaxis, and may have a severe reaction to the vaccine.

As a result, all sites that are injecting the Pfizer-BioNTech COVID-19 vaccine are required to have epinephrine auto-injector devices (Epi-Pens) as a safety precaution if an allergic reaction, occurs after the vaccine is given. Epinephrine, also known as adrenaline, is the only medication recommended as a first-treatment medicine in reversing the life-threatening reaction in an anaphylactic attack.

Continue Reading

ACAAI Releases Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine

ACAAI: Allergic reactions to vaccines rarely occur

Regarding vaccines for immunization against COVID-19, many people have concerns about how safe they are. Are there significant risks of allergic reaction from vaccination? Are adequate procedures being followed? This article provides guidance and recommendations from the American College of Allergy, Asthma and Immunology (ACAAI) an association of allergists-immunologists and allied health professionals.

Covid-19 Vaccination In Arm, Dec. 2020

American College of Allergy, Asthma, and Immunology Releases Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine

December 14th, 2020

With the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine by the FDA on December 11, 2020, and distribution beginning today, the American College of Allergy, Asthma and Immunology COVID-19 Vaccine Task Force recommends the following guidance related to risk of an allergic reaction on vaccination for those who receive the vaccine. These recommendations are based on best knowledge to date but could change at any time, pending new information and further guidance from the FDA or CDC.

Continue Reading

FDA Urges Voluntary Disclosure of Sesame

Dave Bloom at SnackSafely.com regularly provides timely information to families with life-threatening food allergies.

FDA Urges Voluntary Disclosure of Sesame….

FDA logo illustration

….but FDA Falls Short at Protecting Allergic Individuals

By Dave Bloom
October 1 st, 2020

Earlier this week, the US Food and Drug Administration (FDA) issued long-awaited draft guidance regarding the danger of sesame to allergic individuals, urging manufacturers to clearly label for the ingredient. Once again, the FDA falls short in adequately protecting allergic individuals.

The incidence of sesame allergy has skyrocketed and is now the ninth most common food allergy in the US according to the American Association of Allergy, Asthma & Immunology (AAAAI).

Continue Reading

Action Awards Virtual Gala Rated Fun-For-All Success!

Every year the Allergy Advocacy Association Action Awards honor individuals that personify our program of Awareness, Alertness and Action.

Display of the Gala Awards

Action Awards Virtual Gala Rated a Fun-For-All Success!

By Jon Terry
November 15th, 2020

The Allergy Advocacy Association Gala was broadcasted virtually on Wednesday, October 21st. This year the theme of our Allergy Action Awards was a celebration of Halloween featuring "Tricks" rather than "Treats!" Since we were using the world wide web for the very first time we can’t say exactly how many people joined our celebration. We can only hope everyone else had as much fun as we did. Many thanks to one and all who helped make our Virtual Gala & Silent Auction so successful!

Gala Hostess, Brenda Tremblay

This year Brenda Tremblay acted hostess and EMCEE for our celebration. Ms. Tremblay is the (very early!) morning host at WXXI Classical 91.5 FM. Our association is very grateful to Brenda for taking time away from her day job to help our cause. She was a positively wonderful hostess; by wearing a series of very stylish (and humorous!) Halloween hats Brenda established a wonderfully whimsical mood. Brenda's contributions of her time and energy to our association are greatly appreciated!

Continue Reading

The Story Behind the First FDA-Approved Oral Immunotherapy (OIT) for Peanut Allergy

PALFORZIA finally for sale on America's medication marketplace

In addition to changes for food packaging labels, the Food and Drug Administration (FDA) has approved the very first therapy for treatment of peanut allergy.

Dr. Jones with patient

The Story Behind the First FDA-Approved Oral Immunotherapy (OIT) for Peanut Allergy

By Allergic Living
November 9th, 2020

When the U.S. Food and Drug Administration (FDA) approved a new oral immunotherapy (OIT) for peanut allergy in children on January 31, 2020, it marked an important milestone. This biologic OIT drug, called PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-DNFP], became the first treatment approved by the FDA for people who are allergic to peanuts.

Continue Reading

The information provided on this site is in no way intended to be a substitute for medical advice,
diagnosis, or treatment with a licensed physician.
The Allergy Advocacy Association is a 501(c)(3) non-profit, tax-exempt organization.
Copyright 2020 © Allergy Advocacy Association, Inc. All rights reserved.  Terms & Conditions